Persistence and Time to Next Treatment With Ibrutinib Treatment in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Including Patients at High Risk for Atrial Fibrillation or Stroke: A Real-World Study

被引：0
|
作者：
Narezkina, Anna [1 ]
Akhter, Nausheen [2 ]
Lu, Xiaoxiao [3 ]
Emond, Bruno [4 ]
Huang, Qing [3 ]
Panjabi, Sumeet [3 ]
Hilts, Annalise [4 ]
Lu, Stephanie [5 ]
Lafeuille, Helene [4 ]
Lafeuille, Marie-Helene [4 ]
Choi, Michael [6 ]
机构：
[1] Univ Calif San Diego Hlth, San Diego, CA USA
[2] Northwestern Med, Chicago, IL USA
[3] Janssen Sci Affairs LLC, Horsham, PA USA
[4] Anal Grp Inc, Montreal, PQ, Canada
[5] Anal Grp Inc, Menlo Pk, CA USA
[6] Univ Calif San Diego, Moores Canc Ctr, San Diego, CA USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2022年 / 22卷
关键词：
CLL; chronic lymphocytic leukemia/small lymphocytic lymphoma; Bruton's tyrosine kinase inhibitor; time to next treatment; treatment persistence; atrial fibrillation;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CLL-390
引用
收藏
页码：S276 / S277
页数：2
相关论文
共 50 条
  • [41] Real-World Treatment Switching and Sequencing to Next Line of Therapy of Zanubrutinib, Acalabrutinib, and Ibrutinib in Chronic/Small Lymphocytic Leukemia (CLL/SLL)
    Pinilla-Ibarz, Javier
    Xue, Mei
    Wu, Elizabeth
    Esselman, Kaitlyn
    Furnback, Wesley
    Challagulla, Swetha
    Yang, Keri
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S358 - S359
  • [42] Real-World Treatment Patterns and Adverse Events in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib in the UK: A Preliminary Analysis
    Xie, Jing
    Yong, Alan
    Waweru, Catherine
    Sorof, Thuy Anh
    Goyal, Ravi K.
    Davis, Keith L.
    Follows, George
    Hillmen, Peter
    BLOOD, 2019, 134
  • [43] Real-world treatment outcomes in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who were treated with first-line single-agent ibrutinib vs. chemoimmunotherapy
    Wang, Ruibin
    Ding, Zhijie
    Lu, Xiaoxiao
    Mavani, Heena
    He, Jinghua
    Qureshi, Zaina P.
    Pinilla-Ibarz, Javier
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [44] Real-world treatment patterns and outcomes of zanubrutinib in chronic lymphocytic leukemia and small lymphocytic leukemia (CLL/SLL)
    Krackeler, Margaret
    Chee, Bryant
    Orchanian, Arthur K.
    Law, Lisa Y.
    Lopez, Alfredo R.
    Buchanan, Susan
    Maglinte, Gregory A.
    Liu, Raymond
    Zhu, Zheng
    Sakoda, Lori C.
    Tavakoli, Jahan
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [45] Ibrutinib Plus Fludarabine, Cyclophosphamide, and Rituximab As the Treatment for Chronic Lymphocytic Leukemia/ Small Lymphocytic Leukemia: A Single-Center Real World Study
    Zhu, Huayuan
    Shen, Hui
    Yang, Yilian
    Ding, Chong-Yang
    Sha, Yeqin
    Mi, Hongling
    Qiu, Jingyan
    Chen, Ruize
    Wu, Yujie
    Qiao, Chun
    Wang, Li
    Fan, Lei
    Xu, Wei
    Li, Jianyong
    BLOOD, 2020, 136
  • [46] Time to next treatment in patients with chronic lymphocytic leukemia initiating first-line ibrutinib or acalabrutinib
    Jacobs, Ryan
    Lu, Xiaoxiao
    Emond, Bruno
    Morrison, Laura
    Kinkead, Frederic
    Lefebvre, Patrick
    Lafeuille, Marie-Helene
    Khan, Wasiulla
    Wu, Linda H.
    Qureshi, Zaina P.
    Levy, Moshe Yair
    FUTURE ONCOLOGY, 2024, 20 (01) : 39 - 53
  • [47] Real-World Patterns of MRD Testing and Impact on Treatment for Chronic Lymphocytic Leukemia Patients
    Bacchus, Melissa
    Singh-Bulkan, Nivita
    Littleford, Hana E.
    Kim, Joseph
    Martin, Richard L.
    Lacoste, Alix M. B.
    Brimble, Elise
    O'Brien, Conner
    Saltzman, Larry A.
    Greenberger, Lee M.
    Nottke, Amanda
    BLOOD, 2023, 142
  • [48] Real-World Outcome of Treatment with Single-Agent Ibrutinib in Patients with Chronic Lymphocytic Leukemia: Results from the Italian Study Evidence
    Molica, Stefano
    Scalzulli, Potito Rosario
    Scarfo, Lydia
    Guarini, Attilio
    Murru, Roberta
    Sportoletti, Paolo
    Frigeri, Ferdinando
    Albano, Francesco
    Di Renzo, Nicola
    Sanna, Alessandro
    Innocenti, Idanna
    Massaia, Massimo
    Coscia, Marta
    Pennese, Elsa
    Patti, Caterina
    Reda, Gianluigi
    Tafuri, Agostino
    Regazzoni, Giulia
    Di Candia, Michele
    Mauro, Francesca Romana
    BLOOD, 2022, 140 : 4178 - 4180
  • [49] Real-World Outcome of Treatment with Single-Agent Ibrutinib in Italian Patients with Chronic Lymphocytic Leukemia: Final Results of the EVIdeNCE Study
    Mauro, Francesca Romana
    Scalzulli, Potito Rosario
    Scarfo, Lydia
    Minoia, Carla
    Murru, Roberta
    Sportoletti, Paolo
    Frigeri, Ferdinando
    Albano, Francesco
    Di Renzo, Nicola
    Sanna, Alessandro
    Laurenti, Luca
    Massaia, Massimo
    Cassin, Ramona
    Coscia, Marta
    Patti, Caterina
    Pennese, Elsa
    Tafuri, Agostino
    Chiarenza, Annalisa
    Galieni, Piero
    Perbellini, Omar
    Selleri, Carmine
    Califano, Catello
    Ferrara, Felicetto
    Cuneo, Antonio
    Murineddu, Marco
    Palumbo, Gaetano
    Scortechini, Ilaria
    Tedeschi, Alessandra
    Trentin, Livio
    Varettoni, Marzia
    Pane, Fabrizio
    Liberati, Anna Marina
    Merli, Francesco
    Morello, Lucia
    Musuraca, Gerardo
    Tani, Monica
    Ibatici, Adalberto
    Regazzoni, Giulia
    Di Candia, Michele
    Palma, Maria
    Arienti, Danilo
    Molica, Stefano
    CANCERS, 2024, 16 (06)
  • [50] Treatment sequencing and outcomes in patients with chronic lymphocytic leukemia: the informCLL™ real-world registry
    Mato, Anthony
    Ghosh, Nilanjan
    Barrientos, Jacqueline
    Brander, Danielle
    Pagel, John
    Gutierrez, Meghan
    Kadish, Karen
    Tomlinson, Brian
    Ipe, David
    Sundaram, Murali
    Han, Jennifer
    Amaya-Chanaga, Carlos
    Iyengar, Reethi
    Sharman, Jeff
    LEUKEMIA & LYMPHOMA, 2020, 61 : 33 - 36
12345